Microsecond molecular dynamics simulations and dynamic network analysis provide understanding of the allosteric inactivation of GSK3β induced by the L343R mutation
Glycogen synthase kinase 3β (GSK3β), a serine/threonine protein kinase, is involved in several human diseases, including type II diabetes, mood disorders, prostate cancer, and Alzheimer’s disease, representing a potential therapeutic target. GSK3β has a unique specificity, with its primed substrates binding to the primed phosphate binding site, which is critical for the catalytic activity of GSK3β. An L343R mutation located at the C-lobe of GSK3β, remote from the catalytic site, causes kinase inactivation. However, the detailed mechanism of this remains unclear. Here, microsecond molecular dynamics (MD) simulations and network analysis were performed to elucidate the allosteric inactivation of GSK3β triggered by the L343R mutation. Large-scale MD simulations of wild-type and the L343R mutant revealed that the L343R mutation caused disruption of the chemical environment near the mutation site, which propagated remotely to affect the conformational dynamics of the activation loop (A-loop). The resulting conformational rearrangement of the A-loop in the L343R mutant disrupted the primed phosphate binding site, thereby abrogating the catalytic activity of GSK3β. Furthermore, network analysis identified the allosteric pathway from R343 to the primed phosphate binding site in the L343R mutant. Collectively, the results of this study provide a mechanistic explanation of how the L343R mutation allosterically affects the functional activity of GSK3β, which contributes to our understanding of GSK3β biology.
KeywordsAllostery Allosteric pathway Primed substrates Conformational dynamics Phosphorylation
The authors thank the High Performance Supercomputer Center at Shanghai.
The study was supported by the grants from the Natural Science Foundation of China (No. 81372005, 81401851 and 31371011); Scientific Research Projects supported by the Shanghai Committee of Science and Technology (No. 13DZ194808 and 15441904403); Scientific Research Project supported by Shanghai Municipal Commission of Health and Family Planning (No. 20134244).
Compliance with ethical standards
Conflicts of interest
The authors declare that they have no conflict of interest.
- 8.McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, Neri LM, Marmiroli S, Cocco L, Martelli AM (2016) Effects of mutations in Wnt/β-catenin, hedgehog, notch and PI3K pathways on GSK-3 activity-diverse effects on cell growth, metabolism and cancer. Biochim Biophys Acta 1863:2942–2976CrossRefGoogle Scholar
- 13.Tesch R, Becker C, Müller MP, Beck ME, Quambusch L, Getlik M, Lategahn J, Uhlenbrock N, Costa FN, Polêto MD, Pinheiro P de SM, Rodrigues DA, Sant’Anna CMR, Ferreira FF, Verli H, Fraga CAM, Rauh D (2018) An unusual intramolecular halogen bond guides conformational selection. Angew Chemie Int Ed 57:9970–9975CrossRefGoogle Scholar
- 16.Zhang P, Li S, Gao Y, Lu W, Huang K, Ye D, Li X, Chu Y (2014) Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake. Bioorganic Med Chem Lett 24:5639–5643CrossRefGoogle Scholar
- 18.Palomo V, Perez DI, Roca C, Anderson C, Rodríguez-Muela N, Perez C, Morales-Garcia JA, Reyes JA, Campillo NE, Perez-Castillo AM, Rubin LL, Timchenko L, Gil C, Martinez A (2017) Subtly modulating glycogen synthase kinase 3 β: allosteric inhibitor development and their potential for the treatment of chronic diseases. J Med Chem 60:4983–5001CrossRefGoogle Scholar
- 19.Brogi S, Ramunno A, Savi L, Chemi G, Alfano G, Pecorelli A, Pambianchi E, Galatello P, Compagnoni G, Focher F, Biamonti G, Valacchi G, Butini S, Gemma S, Campiani G, Brindisi M (2017) First dual AK/GSK-3β inhibitors endowed with antioxidant properties as multifunctional, potential neuroprotective agents. Eur J Med Chem 138:438–457CrossRefGoogle Scholar
- 30.Howng S-L, Hwang C-C, Hsu C-Y, Hsu M-Y, Teng C-Y, Chou C-H, Lee M-F, Wu C-H, Chiou S-J, Lieu A-S, Loh J-K, Yang C-N, Lin C-S, Hong Y-R (2010) Involvement of the residues of GSKIP, AxinGID, and FRATtide in their binding with GSK3beta to unravel a novel C-terminal scaffold-binding region. Mol Cell Biochem 339:23–33CrossRefGoogle Scholar